Significant efficacy across multiple endpoints
bWith DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood EOS
≥300 cells/μL (DRI12544, secondary endpoint).
cAt Week 52 with DUPIXENT 300 mg + SOC (n=277) vs 230 mL improvement with placebo + SOC (n=142) in patients with baseline blood EOS ≥300 cells/μL (QUEST, secondary endpoint).
dAt Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107) (VENTURE, ITT population).
EOS, eosinophils; ITT, intention-to-treat; OCS, oral corticosteroid; SOC, standard of care.
Mechanism of Action
(MOA)
Only DUPIXENT targets
both IL-4 and IL-13
signaling, two key sources
of local and systemic
type
2 inflammation1-3,a
aThe mechanism of dupilumab action has not
been definitively established.1
Long-term Efficacy and
Safety Data
Explore the TRAVERSE
open-label extension (OLE)
study and see up to ~3
years of efficacy and safety
data6
DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
TESTING REQUIRED
for 99% of OCS-dependent asthma patients who are commercially insured7
Check Formulary
Status
in Your Area
See the insurance coverage status, prior authorization,
and step edit information for DUPIXENT.